Search results for "carcinomas"

showing 10 items of 44 documents

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma

2016

Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metas…

OncologyMaleTime FactorsDatabases FactualCancer Treatmentlcsh:MedicinePredictive Value of TestPediatricsBiochemistryGeographical locationsNeoplasms Multiple PrimaryDecision Support Technique0302 clinical medicineInterquartile rangeRetrospective StudieMultiple PrimaryRisk FactorsNeoplasmsMedicine and Health SciencesEthnicitiesPublic and Occupational HealthLiver DiseasesLiver NeoplasmsChild HealthGeneral MedicineMiddle AgedPrognosisItalian PeopleTumor BurdenQuartileOncologyCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisPredictive value of testsCohortPerspectiveHong Kong030211 gastroenterology & hepatologyFemaleSurvival Analysialpha-FetoproteinsHumanBiotechnologymedicine.medical_specialtyCarcinoma HepatocellularAsiaTime FactorSettore MED/12 - GASTROENTEROLOGIAAged; Carcinoma Hepatocellular; Databases Factual; Decision Support Techniques; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms Multiple Primary; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Taiwan; Time Factors; Tumor Burden; alpha-Fetoproteins; Biotechnology; Biochemistry; Molecular Biology; Cell BiologyTaiwanReproducibility of ResultGastroenterology and HepatologyCarcinomasRisk AssessmentDecision Support Techniques03 medical and health sciencesDatabasesDiagnostic MedicinePredictive Value of TestsInternal medicineGastrointestinal TumorsmedicineHumansNeoplasm Invasivenessalpha-FetoproteinMolecular BiologySurvival analysisFactualAgedNeoplasm StagingRetrospective StudiesNeoplasm InvasivenePerformance statusbusiness.industryRisk Factorlcsh:RCarcinomaCancers and NeoplasmsReproducibility of ResultsRetrospective cohort studyHepatocellularHepatocellular CarcinomaCell BiologySurvival AnalysisBCLC StageSurgeryPeople and PlacesPopulation Groupingsbusiness
researchProduct

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and L…

2020

Background: Lung neuroendocrine carcinoma (NEC) is characterized by aggressive clinical behavior and lack of treatment advances. We evaluate the prognostic and the predictive roles of systemic inflammatory biomarkers in patient circulating blood: neutrophil–lymphocyte ratio (NLR), lactate dehydrogenase (LDH), advanced lung cancer inflammation index (ALI), and the Lung Immune Prognostic Index (LIPI) score. Methods: A total of 120 patients with small-cell lung cancer (SCLC) ( n = 110) and large cell neuroendocrine carcinoma (LCNEC) ( n = 10) were enrolled. Overall survival (OS) was evaluated by Kaplan–Meier estimator and univariate and multivariate Cox proportional hazard analyses were perfor…

Oncologymedicine.medical_specialtyLungBlood based biomarkersbusiness.industrySettore MED/06 - Oncologia Medicasmall-cell lung cancer (SCLC)systemic inflammatory responselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensInflammatory biomarkerslcsh:RC254-282Neuroendocrine Carcinomasmedicine.anatomical_structureOncologyInternal medicinemedicinePrognostic biomarkerNeuroendocrine carcinomaOriginal Articlebusinesspredictive biomarkerprognostic biomarkerneuroendocrine tumorPredictive biomarkerblood-based biomarker
researchProduct

Retrospective analysis of the therapeutic efficacy of platinum/etoposide schedules in the treatment of advanced poor differentiated neuroendocrine ca…

2017

Oncologymedicine.medical_specialtyLungSettore MED/06 - Oncologia Medicabusiness.industryHematologycarcinomas of the lungNeuroendocrine Carcinomasmedicine.anatomical_structureOncologyInternal medicinemedicineRetrospective analysisbusinessEtoposidemedicine.drugAnnals of Oncology
researchProduct

Cetuximab in squamous cell head and neck carcinomas.

2007

The epidermal growth factor receptor (EGFR) antagonist, cetuximab, has recently been shown to enhance the effects of radiotherapy, and reports to date indicate that this effect occurs without any change in the pattern and severity of toxicity usually associated with head and neck radiation and/or chemotherapy (CT) administration. Moreover, several studies have reported that the expression of EGFR is strongly linked to poor outcome in patients undergoing therapy. Therefore, the presence of the EGFR in almost all cases of head and neck carcinoma offers a new therapeutic opportunity to most patients. In this paper, we report a review of the major studies dealing with the use of cetuximab in ad…

Oncologymedicine.medical_specialtyRadiation-Sensitizing Agentsmedicine.medical_treatmentCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedClinical Trials Phase II as TopicInternal medicinemedicineCarcinomaAnimalsHumansEpidermal growth factor receptorSquamous epithelial cellCetuximabbiologyClinical Trials Phase I as Topicbusiness.industryHead and neck cancerAntibodies MonoclonalHematologymedicine.diseaseHead and neck squamous-cell carcinomaChemotherapy regimenRadiation therapyneck carcinomasmedicine.anatomical_structureOncologyHead and Neck Neoplasmsbiology.proteinCarcinoma Squamous CellNeoplasm Recurrence Localbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Vulvar cancer: a review for dermatologists.

2015

Vulvar malignancies are important tumors of the female reproductive system. They represent a serious health issue with an incidence between 2 and 7 per 100,000 and year. We provide a review about most important cancer entities, i.e., melanoma, squamous cell carcinoma, basal cell carcinoma, neuroendocrine cancer, and skin adnexal malignancies. Squamous cell carcinoma is the most common vulvar malignancy that can develop from vulvar intraepithelial neoplasia or de novo. Basal cell carcinoma represents only 2 % of all vulvar cancers. Melanoma of the vulva exists in two major types—superficial spreading and acral lentiginous. A special feature is the occurrence of multiple vulvar melanomas. Of …

Oncologymedicine.medical_specialtySkin NeoplasmsMalignancyVulvaVulvaDiagnosis DifferentialVulva · Squamous cell carcinoma · Basal cell carcinoma · Melanoma · Paget’s disease · Adnexal carcinomasInternal medicineCarcinomamedicineSettore MED/35 - Malattie Cutanee E VenereeHumansBasal cell carcinomaMelanomaNeoplasm StagingSkinintegumentary systemVulvar Neoplasmsurogenital systembusiness.industryMelanomaCancerGeneral MedicineVulvar cancermedicine.diseaseVulvar intraepithelial neoplasiaPrognosisDermatologyfemale genital diseases and pregnancy complicationsNeuroendocrine Tumorsmedicine.anatomical_structurePaget Disease ExtramammaryCarcinoma Basal CellCarcinoma Squamous CellFemaleNeoplasms Adnexal and Skin AppendagebusinessCarcinoma in SituWiener medizinische Wochenschrift (1946)
researchProduct

Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study

2021

Abstract Background Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) play a decisive role as prognostic markers in clear-cell renal cell carcinoma (RCC). To date, the role of PD-1/PD-L1 as a prognostic marker in papillary RCC (pRCC) remains scarce. Patients and Methods Patients’ sample collection was a joint collaboration of the nationwide PANZAR consortium – a multicenter study. Medical history and tumor specimens were collected from 245 and 129 patients with pRCC types 1 and 2, respectively. Expression of PD-1 and PD-L1 was determined by immunohistochemistry in pRCC and tumor-infiltrating mononuclear cells. Results Of 374 pRCC specimens, 204 type 1 and 97 type 2 we…

Oncologymedicine.medical_specialtyUrologyProgrammed Cell Death 1 Receptor030232 urology & nephrology610DiseaseB7-H1 Antigen03 medical and health sciences0302 clinical medicineRenal cell carcinomaInternal medicinePD-L1Biomarkers TumormedicineHumansMedical historyCarcinoma Renal CellPapillary renal cell carcinomasbiologybusiness.industryPrognosismedicine.diseaseKidney NeoplasmsOncology030220 oncology & carcinogenesisCohortbiology.proteinImmunohistochemistrySample collectionbusinessClinical Genitourinary Cancer
researchProduct

Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas

1992

Renal cell tumours are characterized by the loss of chromosome 3p and trisomy of 5q segments (common, non-papillary renal cell carcinoma), or by trisomy of chromosomes 7 and 17 and loss of the Y chromosome (papillary renal cell carcinoma), or by random karyotype changes and mitochondrial DNA alterations (renal oncocytoma). We have studied by means of RFLP analysis the genomic and mitochondrial DNA in 11 chromophobe renal cell carcinomas, which have a unique morphology among kidney cancers. We found a loss of the constitutional heterozygosity at chromosomal regions 3p, 5q, 17p, and 17q, a combination of allelic losses that has not been found in other types of renal cell tumours. Three of the…

Pathologymedicine.medical_specialtyMitochondrial DNAChromophobe Renal Cell CarcinomaChromophobe cellBiologyurologic and male genital diseasesDNA MitochondrialChromosomesPathology and Forensic MedicineLoss of heterozygosityRenal cell carcinomamedicineHumansRenal oncocytomaCarcinoma Renal CellChromosome AberrationsKidneyStaining and LabelingPapillary renal cell carcinomasDNA Neoplasmmedicine.diseaseKidney NeoplasmsBlotting Southernmedicine.anatomical_structurePolymorphism Restriction Fragment LengthThe Journal of Pathology
researchProduct

UP-01.148 E2EPF as an Ubiquitin Carrier Protein Plays a Role in the Cancer Genesis of Papillary Renal Cell Carcinoma

2011

Pathologymedicine.medical_specialtyPapillary renal cell carcinomasUbiquitinbiologyCarrier proteinbusiness.industryUrologybiology.proteinmedicineCancermedicine.diseasebusinessUrology
researchProduct

Analysis of M1 and M2 tumor associated macrophages in tongue squamous cell carcinomas.

2019

Pathologymedicine.medical_specialtymedicine.anatomical_structurePhysiologybusiness.industryTonguePhysiology (medical)CellMedicinebusinesstumor associated macrophages tongue squamous cell carcinomasFrontiers in Physiology
researchProduct

Radial Scar Versus Tubular Carcinoma of the Breast

1995

Summary The present study is focused on the differential diagnosis between radial scar (RS) and tubular carcinoma (TC) using morphometrical and cytophotometrical analysis (static and flow cytometry) of a number of histologically well-established RS cases, (17 lesions) compared with 6 early infiltrating small TC with sclerotic stroma and pseudo-RS fields. One case displayed both RS and TC foci in contiguity. Mean nuclear area was larger in the group of tubular carcinomas (51.0 μ 2 ) than in the cases o f radial sclerosis (38.30 μ 2 ). We also found a larger number of aneuploid cases in tubular carcinomas measured by image cytometry, but both types o f lesions were diploid when measured by fl…

Pathologymedicine.medical_specialtymedicine.diagnostic_testRadial scarNuclear areaTubular CarcinomasCell BiologyBiologymedicine.diseasePathology and Forensic MedicineFlow cytometryStromamedicineImage CytometryTubular carcinomaDifferential diagnosisPathology - Research and Practice
researchProduct